Alnylam Pharmaceuticals, Inc. (ALNY)
-NasdaqGS 30.25 
0.26(0.87%) 3:59PM EDT|After Hours
:
30.25 0.00 (0.00%) 4:07PM EDT
| Prev Close: | 29.99 |
|---|
| Open: | 30.04 |
|---|
| Bid: | 29.70 x 300 |
|---|
| Ask: | 33.00 x 200 |
|---|
| 1y Target Est: | 32.17 |
|---|
| Beta: | 1.94 |
|---|
| Next Earnings Date: | 5-Aug-13 |
|---|
| Day's Range: | 29.70 - 30.84 |
|---|
| 52wk Range: | 11.26 - 31.79 |
|---|
| Volume: | 659,074 |
|---|
| Avg Vol (3m): | 399,456 |
|---|
| Market Cap: | 1.88B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -1.94 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- Commit To Buy Alnylam Pharmaceuticals At $25, Earn 22.8% Annualizedat Forbes(Mon, Jun 17)
- 2 Biotechs With Recent Intensive Insider Sellingat Seeking Alpha(Sun, Jun 16)
- Alnylam Pharmaceuticals' Management Presents at the Goldman Sachs 34th Annual Global Healthcare Conference (Transcript)at Seeking Alpha(Thu, Jun 13)
- Tekmira Pharmaceuticals: An Interesting Long-Term Investmentat Seeking Alpha(Thu, Jun 13)
- ALNYLAM PHARMACEUTICALS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security HoldersEDGAR Online(Mon, Jun 10)
- Cramer Says Buy Krispy Kreme Doughnuts, Allstate, Alnylam, But Sell These 2 Stocksat Wall St. Cheat Sheet(Fri, Jun 7)
- Cramer's Lightning Round - The All-Clear For Allstate (6/6/13)at Seeking Alpha(Fri, Jun 7)
- Biotech Stock Mailbag: 2013 Clinical Trials Calendarat TheStreet(Fri, Jun 7)
- 'Mad Money' Lightning Round: I Like Allstateat TheStreet(Fri, Jun 7)
- Lightning Round: Visa, Micron & Moreat CNBC(Thu, Jun 6)
- [video] Lightning Roundat CNBC(Thu, Jun 6)
- Alnylam to Webcast Presentation at Goldman Sachs 34th Annual Global Healthcare ConferenceBusiness Wire(Thu, Jun 6)
- 3 Pharmaceuticals With Strong Potentialat Seeking Alpha(Wed, Jun 5)
- CHMP Positive on Aegerion's LojuxtaZacks(Mon, Jun 3)
- Alnylam Pharmaceuticals' CEO Presents at 38th Annual dbAccess Health Care Conference (Transcript)at Seeking Alpha(Wed, May 29)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 28.78 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -1.28 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.34 |
|---|
| Mean Recommendation*: | 2.1 |
|---|
| PEG Ratio (5 yr expected): | 3.56 |
|---|
Business Summary
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing novel therapeutics based on RNA interference (RNAi).
View More